These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17008827)

  • 41. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
    Lee JH; Dunner DL
    Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine.
    Entsuah R; Gorman JM
    J Psychiatr Res; 2002; 36(3):111-8. PubMed ID: 11886688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Items Predicting Non-Remission after 6 Months of Treatment of Patients with Generalized Anxiety Disorder Covered the Eysenck Neuroticism Components of Anxiety, Interpersonal Sensitivity and Depression.
    Bech P; Rickels K
    Psychother Psychosom; 2016; 85(4):229-30. PubMed ID: 27230864
    [No Abstract]   [Full Text] [Related]  

  • 44. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
    Adams JB; Pyke RE; Costa J; Cutler NR; Schweizer E; Wilcox CS; Wisselink PG; Greiner M; Pierce MW; Pande AC
    J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis.
    Schmitt R; Gazalle FK; Lima MS; Cunha A; Souza J; Kapczinski F
    Braz J Psychiatry; 2005 Mar; 27(1):18-24. PubMed ID: 15867979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.
    Khan A; Durgam S; Tang X; Ruth A; Mathews M; Gommoll CP
    Prim Care Companion CNS Disord; 2016; 18(2):. PubMed ID: 27486544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined medication and cognitive therapy for generalized anxiety disorder.
    Crits-Christoph P; Newman MG; Rickels K; Gallop R; Gibbons MB; Hamilton JL; Ring-Kurtz S; Pastva AM
    J Anxiety Disord; 2011 Dec; 25(8):1087-94. PubMed ID: 21840164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generalized anxiety disorder in family practice patients.
    Magill MK; Gunning K
    Am Fam Physician; 2000 Oct; 62(7):1497, 1501-2, 1504. PubMed ID: 11037071
    [No Abstract]   [Full Text] [Related]  

  • 49. Recent clinical trials of hydroxyzine in generalized anxiety disorder.
    Ferreri M; Hantouche EG
    Acta Psychiatr Scand Suppl; 1998; 393():102-8. PubMed ID: 9777055
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder.
    Bereza BG; Machado M; Ravindran AV; Einarson TR
    Can J Psychiatry; 2012 Aug; 57(8):470-8. PubMed ID: 22854029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined medication and CBT for generalized anxiety disorder with African American participants: reliability and validity of assessments and preliminary outcomes.
    Markell HM; Newman MG; Gallop R; Gibbons MB; Rickels K; Crits-Christoph P
    Behav Ther; 2014 Jul; 45(4):495-506. PubMed ID: 24912462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse events in placebo-treated patients with generalized anxiety disorder.
    Sramek JJ; Frackiewicz EJ; Piercy MA; Kurtz NM; Murphy MF; Carta A; Cutler NR
    Depress Anxiety; 1997; 5(3):142-3. PubMed ID: 9323457
    [No Abstract]   [Full Text] [Related]  

  • 53. Application of the Stages of Change Scale in a clinical drug trial.
    Wilson M; Bell-Dolan D; Beitman B
    J Anxiety Disord; 1997; 11(4):395-408. PubMed ID: 9276784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Defining Treatment Response and Remission in Youth Anxiety: A Signal Detection Analysis With the Multidimensional Anxiety Scale for Children.
    Palitz SA; Caporino NE; McGuire JF; Piacentini J; Albano AM; Birmaher B; Walkup JT; Compton SN; Ginsburg GS; Kendall PC
    J Am Acad Child Adolesc Psychiatry; 2018 Jun; 57(6):418-427. PubMed ID: 29859557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Problems investigating efficacy in anxiety states.
    Schweizer E
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():57-61. PubMed ID: 7911141
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of pharmacotherapy for anxiety disorders on quality of life: a meta-analysis.
    Hofmann SG; Wu JQ; Boettcher H; Sturm J
    Qual Life Res; 2014 May; 23(4):1141-53. PubMed ID: 24241771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?
    Baldwin DS
    CNS Spectr; 2006 Oct; 11(10 Suppl 12):34-9. PubMed ID: 17008829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The largest meta-analysis of pharmaceutical treatments of Generalised Anxiety Disorder consolidates current knowledge and reveals convincing effectiveness of Venlafaxine.
    Roles S
    Evid Based Nurs; 2020 Jul; 23(3):74. PubMed ID: 31138563
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacological treatments for generalised anxiety disorder.
    Zhou Q; Yang N; Yang K; Estill J; Chen Y
    Lancet; 2019 Oct; 394(10205):1229. PubMed ID: 31591980
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacological treatments for generalised anxiety disorder - Authors' reply.
    Freemantle N; Slee A; Nazareth I
    Lancet; 2019 Oct; 394(10205):1230. PubMed ID: 31591982
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.